Introduction

Establishing survival-prognosis of the individual patient is of uppermost interest, so there is intense focus on finding tumor-related prognostic factors to influence clinical decisions on operative treatment and the further therapeutic concept1,2,3.

Liposarcomas represent a spectrum of malignant tumors with adipocytic differentiation and are one of the most common subtypes of soft tissue sarcoma (STS). The 5-year survival rates are between 57 and 95%. The clinical presentation is versatile, appearing on all body parts, but cumulatively on extremities and the retroperitoneum and the course of the disease is difficult to predict4,5,6,7.

The main histological subtypes are: atypical lipomatous tumor (ALT)/well differentiated liposarcoma, myxoid/round cell liposarcoma, dedifferentiated liposarcoma and pleomorphic liposarcoma4,8. The pathological subclassification and histologic grade are key prognostic factors for survival (Hannibal, Rutkowski): while ALT only carry a risk of local recurrence, the pleomorphic and dedifferentiated liposarcomas are high-grade malignancies with a substantial risk of metastatic disease4,7,9. Tumor size, depth, site, grade, age at diagnosis and resection margins have been associated with overall survival (OS) in STS6,7.

In recent studies the concept of the involvement of systemic inflammation and acute phase proteins in cancer progression and metastasis has been postulated. Specifically, elevated preoperative CRP and neutrophil/lymphocyte ratio (NLR) as markers of systemic inflammatory response have been found to be associated with decreased overall survival in various cancers10,11,12,13,14,15,16,17,18.

Furthermore, lower levels of serum albumin are considered to be an indicator of current systemic immune response to tumor cell products and inflammatory cytokines. Correspondingly, biomarkers of kidney dysfunction were identified to predict inpatient mortality. Elevated serum creatinine, low albumin, and a decreased albumin–creatinine ratio (ACR) were found to be negative prognostic factor with worse disease specific survival in patients with myofibroblastic and fibroblastic sarcoma as well as liposarcoma19,20.

Interestingly, also a link between certain proteins of haemostasis and tumor progression was evidenced in previous studies17,21,22,23. Ay et al. showed that high d-dimer levels, as a biomarker indicating the activation of haemostasis and fibrinolysis, are associated with poor overall survival and increased mortality risk in cancer patients24,25.

In observational studies, fibrinogen, which is an essential protein for blood clot formation and also an acute phase protein, was described as an useful prognostic biomarker for several malignancies17,21,26,27.

The impact of plasma levels of fibrinogen on risk of mortality and survival in patients with soft tissue sarcoma has been described, however, the value in association with liposarcoma has not yet been elucidated.

The aim of the present study was to investigate plasma levels of fibrinogen as a prognostic biomarker in patients with liposarcoma.

Patients and methods

The study population consisted of a total of 184 patients with histologically confirmed liposarcoma, that were treated at the Department of Orthopaedic Surgery, Medical University of Vienna from 1994 to 2021. All patients were followed-up until July 2021 at our department with a standardized interval, which contains examinations every 3 months during the first 3 years, every 6 months in year 4 and 5 and in 12-month intervals after that.

Post-operative surveillance incorporated clinical examination, ultrasound of the abdomen, computed tomography scans of the thorax and local magnetic resonance imaging.

A cut-off of 12 weeks was defined and excluded all patients (patients who have been operated on account of their sarcoma at an outside clinic prior referral to our department because of insufficient excision or nonradical resection margins) with a longer duration between index surgery and referral to our clinic. The study population incorporates 158 patients with complete clinical pathological data (i.e. the final study population) and retrospectively, the corresponding data was collected from medical reports (sex, age, laboratory parameters, tumor site, tumor size, tumor depth, histology, resection margins, tumor stage, neoadjuvant and adjuvant radiotherapy, adjuvant chemotherapy, local recurrence).

In the study population, 11 patients (6.96%) received preoperative radiotherapy.

Laboratory data from routine inquiries were acquired within 2 weeks before surgical treatment and the minimum interval to radiotherapy is 22 days.

Histopathological analysation, as well as diagnoses, were done in accordance with to the current WHO classification for soft tissue and bone tumors and validated at our clinic by an proficient pathologist specialised in STS8. According to AJCC criteria, tumor stage was generated29, Resection margins were allocated following Enneking et al.28 and grading (i.e. G1–G3) according to the French Federation of Cancer Centres Sarcoma Group (FNCLCC) grading system)30.

This work was given approval by our local ethics committee of the Medical University of Vienna, Austria. We conform that all methods took place in accordance with relevant guidelines and regulations, under informed consent from all participants.

Level of evidence III (retrospective cohort study).

Statistical analysis

For any statistical analyses and graphical visualization IBM SPSS Statistics, Version 27, SPSS Inc, Chicago, IL, USA, was utilized. Continuous data was summarized, using mean values, medians and ranges and categorical data by absolute frequencies and percentages. For the calculation of correlations, Spearmann’s correlation coefficient was applied. Baseline was determined as the day of first diagnosis and the endpoint (overall survival) was defined as death from any cause, which in this study could carefully be considered as equal of death of disease. We considered follow-up time as the timespan from index surgery to death or last known alive. Calculation of survival probabilities were computed with the Kaplan–Meier product limit estimator. For this purpose, serum Fibrinogen levels were categorized into < 450 and ≥ 450 mg/dL. Comparison of the survival functions of two or more patient groups, were applied with the log-rank test. Further, for the evaluation of the relation between baseline variables and survival, uni- and multivariable Cox proportional hazards regression models were fitted. Calculation of the multivariable model was computed with the co-variable AJCC tumor stage. P values < 0.05 were considered to indicate statistical significance.

Results

The median age of the total study population was 66.4 (range 7–99) years and the median follow-up time 37.5 months (range 1–228.8 months). The median baseline fibrinogen level (g/L) was 353.0 (range 132.0–956.0).

The primary tumor was located as follows: extremities in 137 cases (86.7%), trunk in 12 (7.7%) and other location in 9 (5.7%).

The baseline study population characteristics are shown in Table 1.

Table 1 Baseline characteristics of the study population.
Full size table

In cause specific hazards analysis of overall survival, elevated fibrinogen was associated with adverse overall survival (hazard ratio [HR] per 10 mg/dL increase: 1.04; 95% CI 1.02–1.06; p < 0.001). This association prevailed after adjustment for AJCC tumor stage (HR 1.03; 95% CI 1.01–1.05; p = 0.013) in multivariable analysis.

Fibrinogen is highly correlated with both CRP, NLR and Alkalic Phosphatase (ρ = 0.38; p < 0.001, ρ = 0.18; p = 0.024 and ρ = 0.39; p < 0.001). Moreover, there is strong evidence for an inverse correlation between haemoglobin and fibrinogen (ρ = − 0.19, p = 0.014). There was no correlation with tumor size.

Patients with pre-operative fibrinogen levels ≥ 450 mg/dL (n = 33) had a lower survival rate than patients with fibrinogen levels < 450 mg/dL (n = 125) (Log Rank p < 0.001) (survival rates of 78.5% vs. 24.0%). Kaplan–Meier survival analysis is shown in Fig. 1. The overall survival rate was 77.9%.

Figure 1
figure 1

Kaplan–Meier survival analysis in patients with liposarcoma distributed by preoperative fibrinogen levels.

Full size image

Discussion

In the present study, we identified a significant association between plasma fibrinogen and overall survival.

Fibrinogen is a key protein in the coagulation pathway and represents one of the major acute phase proteins31. Moreover, plasma fibrinogen has been reported to be synthesized and overexpressed in human neoplasia cells32. Fibrinogen itself induces the synthesis of pro-inflammatory cytokines and modulates immune activity31,33. Cancer cells may interact directly and indirectly with host inflammatory cells33. In recent studies, the concept of the involvement of systemic inflammation in cancer progression and metastasis has been postulated. Specifically, elevated preoperative CRP as marker of systemic inflammatory response have been found to be associated with decreased overall survival12,16,34,35,36,37,38,39,40.

Previous reports showed that elevated fibrinogen levels were associated with adverse outcome for the following reasons: Fibrinogen may enhance tumor progression and the development of tumor spread through the following mechanism: tumor cells prefer to adhere to fibrinogen and secondly fibrinogen enhances the adhesion of tumor cells to platelets which may protect tumor cells from immune answer41,42,43.

Plasma fibrinogen was described as useful prognostic biomarker for other malignancies (Ovarian Cancer44, Gastric cancer45 Renal cell Carcinoma21, Hepatocellular Carcinoma46, solid tumors27 and also for Soft tissue Sarcoma in general17 but not for Liposarcoma per se. Our findings are in line with the studies mentioned before and are clinically plausible.

While we are aware of the limitations of the present study (retrospective design, sample size prevalent cases), the strength of our report is that we report about a single center population of liposarcoma patients, although histological subtypes of liposarcoma have to be distinguished.

Furthermore, a possible effect of preoperative radiotherapy on fibrinogen levels needs to be addressed. In fact, there is some data on the increase of fibrinogen synthesis after irradiation therapy. Maximum increase is reached about 4–6 days after irradiation47.

Since the half-life of fibrinogen is about 3–5 days, the minimum interval between irradiation and blood sampling was at least 22 days and only a few patients have received neoadjuvant irradiation, our results may be assumed to be valid48.

Furthermore, there is a minimum interval of 5 weeks between last irradiation and performed surgery.

Previous studies reported that there is no significant difference in outcome when re-resection is performed within 12 weeks after initial surgery49. The inclusion of the prevalent cases in the present study may not reflect a survivorship bias because we set the cut off of the prevalent cases of 12 weeks and excluded all patients that had a longer duration between initial surgery and re-resection.

Conclusion

Fibrinogen is easy to assess and is an established laboratory parameter used in daily clinical routine. A benefit of this biomarker could be to create an individual risk profile and predict the clinical outcome and in consequence have an influence on the extent of treatment and posttreatment morbidity.